A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic ...

As we continue to see sequencing technologies advance and provide a deeper understanding of gene therapy targets along with ...

Cell and gene therapies (CGTs) are revolutionizing the landscape of personalized medicine, offering treatments that were once ...

Innovative financing and reimbursement models can improve access to cell and gene therapies, addressing cost barriers and ...

Factor Bioscience Inc., a Cambridge-based biotechnology company focused on using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced its participation ...

Forge Biologics ("Forge"), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, ...

Base-editing technologies along with AAV engineering not only help reduce costs but can also accelerate preclinical therapeutic development.

Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue, while reporting ...

Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its ...

Fran Gregory, VP, emerging therapies, Cardinal Health, emphasizes the need for long-term outcomes tracking and robust health economic modeling to demonstrate the sustained value of advanced therapies ...

Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders ...

Veeva Systems today announced its keynote speakers for the 2025 Veeva Commercial Summit, May 13-14 in Boston. Leading and emerging biopharmas will share innovations and strategies to drive more ...